EU Clears 700-mg Every-6-Week Cemiplimab Dosing Across All Six Indications
![<![CDATA[EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers]]>](/media/e7/e72fd27b4b6457d4.1280.webp)
The European Commission has approved cemiplimab (Libtayo) at 700 mg every 6 weeks — after 12 weeks at 350 mg every 3 weeks — across all six of its EU indications in skin, lung and cervical cancer, and it allows 350-mg infusions to run as short as 15 minutes once the first 30-minute infusion is well tolerated. The decision, dated November 17, 2026, halves dosing frequency after the first three months of treatment.
Until now, the every-6-week option existed in the EU only for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence; every other indication required 350 mg every 3 weeks over 30 minutes. The change followed a positive October 2026 opinion from the EMA's Committee for Medicinal Products for Human Use.
What does the new regimen look like?
Under the approved schedule, patients start with 350 mg by 30-minute IV infusion every 3 weeks for 12 weeks, then switch to 700 mg by 30-minute IV infusion every 6 weeks. Patients who stay on the every-3-week dose can receive subsequent infusions over 15 to 30 minutes if their first 30-minute infusion was well tolerated. Regeneron says the shorter infusions improve suite throughput; the approval itself rests on pharmacokinetic and pharmacodynamic modeling and simulation plus pooled safety and efficacy data from the clinical program.
Israel Lowy, MD, PhD, Senior Vice President and Oncology Clinical Development Unit Head at Regeneron, framed the practical stakes: "By offering an every-6-week maintenance schedule, and potentially halving infusion times for the every-three-week dose, we can help ease the burden of frequent clinic visits and longer infusion times for patients, while giving healthcare providers greater flexibility."
For a patient on maintenance therapy, that means six fewer infusion appointments per year.
Which indications are covered?
The schedule now spans cemiplimab's full EU label:
- CSCC: monotherapy for metastatic or locally advanced disease not amenable to curative surgery or radiation, plus adjuvant monotherapy after surgery and radiation in high-risk disease.
- Basal cell carcinoma: monotherapy for locally advanced or metastatic disease that progressed on or was intolerant to a hedgehog pathway inhibitor.
- NSCLC, first line: monotherapy for tumors with PD-L1 expression in at least 50% of tumor cells; cemiplimab plus platinum chemotherapy for PD-L1 expression in at least 1% of cells. Both require no EGFR, ALK or ROS1 aberrations.
- Cervical cancer: monotherapy for recurrent or metastatic disease progressed on or after platinum-based chemotherapy.
Cemiplimab, a fully human monoclonal antibody against the PD-1 checkpoint on T cells, is approved in at least one indication in more than 30 countries.
What did the C-POST trial show?
The every-6-week schedule was studied in the phase 3 C-POST trial (NCT03969004), which enrolled patients with high-risk CSCC after surgery and postoperative radiation and randomized them 1:1 to adjuvant cemiplimab or placebo. After a June 29, 2021 protocol amendment, dosing ran 350 mg every 3 weeks for 12 weeks, then 700 mg every 6 weeks for up to 36 weeks — 48 weeks total. Disease-free survival was the primary endpoint.
At a median follow-up of 24 months, DFS events occurred in 24 of 209 cemiplimab patients versus 65 of 206 placebo patients (HR, 0.32; 95% CI, 0.20–0.51; P < .001). The estimated 24-month DFS rate was 87.1% with cemiplimab versus 64.1% with placebo. Because the schedule changed mid-trial, these results don't isolate the efficacy of the every-6-week interval itself.
Lead investigator Danny Rischin, MD, MBBS, FRACP, of the Peter MacCallum Cancer Centre in Melbourne, called the data "compelling evidence of the long-term, durable benefit of adjuvant treatment with Libtayo in high-risk CSCC after surgery and radiation" in an October 2026 release.
When does the US follow?
A US supplemental biologics license application for the regimen is under FDA review, with a decision expected in March 2027. The US label already carries the 700-mg every-6-week schedule for adjuvant high-risk CSCC, approved in October 2025 — so an American extension to the remaining indications would be the next domino, and clinicians on both sides of the Atlantic will be watching infusion-center logistics as much as efficacy when it lands.
Source: onclive.com
Daniel Okafor
Show full bio
Staff writer covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.